In recent years, with the increasingly serious global microbial resistance and pathogen mutation problem, in vitro diagnostic of infectious diseases has become a major academic research hot spot of major pharmaceutical technology companies. With the increasing prevalence of infectious diseases, testing needs are on the increase. It’s estimated that by 2020, the infectious diseases test market will increase from 16.8 billion dollars in 2015 to 20.9 billion dollars.
At present, there are two types of infectious diseases that still have broad clinical needs.
Hepatitis is a infectious disease with particularly high incidence in the world, and clinically mainly refers to hepatitis B (HBV) and hepatitis C (HCV).
Currently, clinical diagnosis of hepatitis usually adopts antigen immunoassay and molecular diagnostic techniques.
2. Sexually transmitted diseases and gynecological health testing
Among sexually transmitted diseases (STD) and gynecological-related examination tools, the most widely used is molecular diagnostic kits for its convenience and compactness, etc., and it becomes the hottest tool in STD and gynecological diagnosis over the five years.
At present, STD pathogens are still laboratory-based. The existing STD disease test kits mainly include improved Treponema pallidum antibody rapid detection kit and HIV-syphilis multiple rapid detection box.